AdvanCell Series D

AdvanCell has secured a $315 million Series D funding round, an oversubscribed follow-on round, to accelerate its targeted alpha therapies. The company plans to utilize these funds to advance its clinical pipeline, which includes lead candidate AC-01 for prostate cancer, and expand its manufacturing capabilities. This financing was led by new investor Perceptive Advisors, with participation from existing investors including RA Capital Management and Frazier Healthcare Partners.